191 related articles for article (PubMed ID: 11468194)
21. In vitro activity of the flt3-inhibitor su5614 and standard cytotoxic agents in tumour cells from patients with wild type and mutated flt3 acute myeloid leukaemia.
Aleskog A; Höglund M; Pettersson J; Hermansson M; Larsson R; Lindhagen E
Leuk Res; 2005 Sep; 29(9):1079-81. PubMed ID: 16038735
[TBL] [Abstract][Full Text] [Related]
22. FLT3 mutations in acute myeloid leukemia cell lines.
Quentmeier H; Reinhardt J; Zaborski M; Drexler HG
Leukemia; 2003 Jan; 17(1):120-4. PubMed ID: 12529668
[TBL] [Abstract][Full Text] [Related]
23. CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML).
Kelly LM; Yu JC; Boulton CL; Apatira M; Li J; Sullivan CM; Williams I; Amaral SM; Curley DP; Duclos N; Neuberg D; Scarborough RM; Pandey A; Hollenbach S; Abe K; Lokker NA; Gilliland DG; Giese NA
Cancer Cell; 2002 Jun; 1(5):421-32. PubMed ID: 12124172
[TBL] [Abstract][Full Text] [Related]
24. Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia.
Meshinchi S; Woods WG; Stirewalt DL; Sweetser DA; Buckley JD; Tjoa TK; Bernstein ID; Radich JP
Blood; 2001 Jan; 97(1):89-94. PubMed ID: 11133746
[TBL] [Abstract][Full Text] [Related]
25. Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations for acute myeloid leukemia: a meta-analysis.
Yanada M; Matsuo K; Suzuki T; Kiyoi H; Naoe T
Leukemia; 2005 Aug; 19(8):1345-9. PubMed ID: 15959528
[TBL] [Abstract][Full Text] [Related]
26. Suppression of myeloid transcription factors and induction of STAT response genes by AML-specific Flt3 mutations.
Mizuki M; Schwable J; Steur C; Choudhary C; Agrawal S; Sargin B; Steffen B; Matsumura I; Kanakura Y; Böhmer FD; Müller-Tidow C; Berdel WE; Serve H
Blood; 2003 Apr; 101(8):3164-73. PubMed ID: 12468433
[TBL] [Abstract][Full Text] [Related]
27. FLT3 and its role in the pathogenesis of acute myeloid leukaemia.
Reilly JT
Leuk Lymphoma; 2003 Jan; 44(1):1-7. PubMed ID: 12691136
[TBL] [Abstract][Full Text] [Related]
28. Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia.
Smith BD; Levis M; Beran M; Giles F; Kantarjian H; Berg K; Murphy KM; Dauses T; Allebach J; Small D
Blood; 2004 May; 103(10):3669-76. PubMed ID: 14726387
[TBL] [Abstract][Full Text] [Related]
29. RGS2 is an important target gene of Flt3-ITD mutations in AML and functions in myeloid differentiation and leukemic transformation.
Schwäble J; Choudhary C; Thiede C; Tickenbrock L; Sargin B; Steur C; Rehage M; Rudat A; Brandts C; Berdel WE; Müller-Tidow C; Serve H
Blood; 2005 Mar; 105(5):2107-14. PubMed ID: 15536149
[TBL] [Abstract][Full Text] [Related]
30. Internal tandem duplication of fms-like tyrosine kinase 3 is associated with poor outcome in patients with myelodysplastic syndrome.
Shih LY; Lin TL; Wang PN; Wu JH; Dunn P; Kuo MC; Huang CF
Cancer; 2004 Sep; 101(5):989-98. PubMed ID: 15329908
[TBL] [Abstract][Full Text] [Related]
31. Prediction of resistance to small molecule FLT3 inhibitors: implications for molecularly targeted therapy of acute leukemia.
Cools J; Mentens N; Furet P; Fabbro D; Clark JJ; Griffin JD; Marynen P; Gilliland DG
Cancer Res; 2004 Sep; 64(18):6385-9. PubMed ID: 15374944
[TBL] [Abstract][Full Text] [Related]
32. Receptor tyrosine kinase Axl is required for resistance of leukemic cells to FLT3-targeted therapy in acute myeloid leukemia.
Park IK; Mundy-Bosse B; Whitman SP; Zhang X; Warner SL; Bearss DJ; Blum W; Marcucci G; Caligiuri MA
Leukemia; 2015 Dec; 29(12):2382-9. PubMed ID: 26172401
[TBL] [Abstract][Full Text] [Related]
33. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies.
Yamamoto Y; Kiyoi H; Nakano Y; Suzuki R; Kodera Y; Miyawaki S; Asou N; Kuriyama K; Yagasaki F; Shimazaki C; Akiyama H; Saito K; Nishimura M; Motoji T; Shinagawa K; Takeshita A; Saito H; Ueda R; Ohno R; Naoe T
Blood; 2001 Apr; 97(8):2434-9. PubMed ID: 11290608
[TBL] [Abstract][Full Text] [Related]
34. BH3-only protein Bim more critical than Puma in tyrosine kinase inhibitor-induced apoptosis of human leukemic cells and transduced hematopoietic progenitors carrying oncogenic FLT3.
Nordigården A; Kraft M; Eliasson P; Labi V; Lam EW; Villunger A; Jönsson JI
Blood; 2009 Mar; 113(10):2302-11. PubMed ID: 19064725
[TBL] [Abstract][Full Text] [Related]
35. CHIR-258: a potent inhibitor of FLT3 kinase in experimental tumor xenograft models of human acute myelogenous leukemia.
Lopes de Menezes DE; Peng J; Garrett EN; Louie SG; Lee SH; Wiesmann M; Tang Y; Shephard L; Goldbeck C; Oei Y; Ye H; Aukerman SL; Heise C
Clin Cancer Res; 2005 Jul; 11(14):5281-91. PubMed ID: 16033847
[TBL] [Abstract][Full Text] [Related]
36. Enforced expression of an Flt3 internal tandem duplication in human CD34+ cells confers properties of self-renewal and enhanced erythropoiesis.
Chung KY; Morrone G; Schuringa JJ; Wong B; Dorn DC; Moore MA
Blood; 2005 Jan; 105(1):77-84. PubMed ID: 15242879
[TBL] [Abstract][Full Text] [Related]
37. SU5416 and SU5614 inhibit kinase activity of wild-type and mutant FLT3 receptor tyrosine kinase.
Yee KW; O'Farrell AM; Smolich BD; Cherrington JM; McMahon G; Wait CL; McGreevey LS; Griffith DJ; Heinrich MC
Blood; 2002 Oct; 100(8):2941-9. PubMed ID: 12351406
[TBL] [Abstract][Full Text] [Related]
38. Selective cytotoxic mechanism of GTP-14564, a novel tyrosine kinase inhibitor in leukemia cells expressing a constitutively active Fms-like tyrosine kinase 3 (FLT3).
Murata K; Kumagai H; Kawashima T; Tamitsu K; Irie M; Nakajima H; Suzu S; Shibuya M; Kamihira S; Nosaka T; Asano S; Kitamura T
J Biol Chem; 2003 Aug; 278(35):32892-8. PubMed ID: 12815052
[TBL] [Abstract][Full Text] [Related]
39. Incidence and prognostic value of FLT3 internal tandem duplication and D835 mutations in acute myeloid leukemia.
Moreno I; Martín G; Bolufer P; Barragán E; Rueda E; Román J; Fernández P; León P; Mena A; Cervera J; Torres A; Sanz MA
Haematologica; 2003 Jan; 88(1):19-24. PubMed ID: 12551822
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of a Mer and Flt3 tyrosine kinase small molecule inhibitor, UNC1666, in acute myeloid leukemia.
Lee-Sherick AB; Zhang W; Menachof KK; Hill AA; Rinella S; Kirkpatrick G; Page LS; Stashko MA; Jordan CT; Wei Q; Liu J; Zhang D; DeRyckere D; Wang X; Frye S; Earp HS; Graham DK
Oncotarget; 2015 Mar; 6(9):6722-36. PubMed ID: 25762638
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]